Authorized purpose: Aibolit 3D+ processes, reviews, analyzes, communicates, and exchanges multidimensional digital images acquired from CT and MR devices for preoperative surgical planning, training, patient information, and intraoperative display, assisting the clinician responsible for final patient-management decisions.
Clinical role
Medical-image viewing, processing, segmentation, measurement, registration, communication, or planning support within the exact labeled scope.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Patient-specific anatomy represented in CT and MR images for preoperative or intraoperative planning
Key limitation
Keep in mind: Supported modalities, modules, anatomy, patient population, and output use are submission-specific; source images and generated results require expert review.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Aibolit 3D+ processes, reviews, analyzes, communicates, and exchanges multidimensional digital images acquired from CT and MR devices for preoperative surgical planning, training, patient information, and intraoperative display, assisting the clinician responsible for final patient-management decisions.
Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Patient-specific anatomy represented in CT and MR images for preoperative or intraoperative planning Input: DICOM or other medical-image data from the exact labeled modalities, scanners, and user workflow.
Who uses it?Intended users: Trained healthcare professionals, physicians, technicians, surgeons, or other users specified by the exact submission.
What does the software produce?Output: Images, measurements, segmentations, models, reports, or planning information for professional review.
What is its most important limitation?Key limitation: Supported modalities, modules, anatomy, patient population, and output use are submission-specific; source images and generated results require expert review.
Clinical takeaway. Clinical role: Aibolit 3D+ processes, reviews, analyzes, communicates, and exchanges multidimensional digital images acquired from CT and MR devices for preoperative surgical planning, training, patient information, and intraoperative display, assisting the clinician responsible for final patient-management decisions.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports non-clinical performance data: software verification and validation, segmentation validation of the Customize software, a repeatability and reproducibility study of segmentation of multiple organ/structure anatomies, and an accuracy study of 3D model generation. An added MRI validation, under a written protocol with pre-determined acceptance criteria and using multiple organ structures, radiologists, and view perspectives, demonstrated conservation of shape dimensions and volume versus a ground truth accepted standard. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Aibolit 3D+ processes, reviews, analyzes, communicates, and exchanges multidimensional digital images acquired from CT and MR devices for preoperative surgical planning, training, patient information, and intraoperative display, assisting the clinician responsible for final patient-management decisions.
Supported modalities, modules, anatomy, patient population, and output use are submission-specific; source images and generated results require expert review.
The exact FDA document reports non-clinical performance data: software verification and validation, segmentation validation of the Customize software, a repeatability and reproducibility study of segmentation of multiple organ/structure anatomies, and an accuracy study of 3D model generation. An added MRI validation, under a written protocol with pre-determined acceptance criteria and using multiple organ structures, radiologists, and view perspectives, demonstrated conservation of shape dimensions and volume versus a ground truth accepted standard. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Non-clinical performance data was included in the 510(k) submission to demonstrate that the Aibolit software has been validated for its intended use" … "Software verification and validation were performed, and documentation was included in this submission". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports non-clinical performance data: software verification and validation, segmentation validation of the Customize software, a repeatability and reproducibility study of segmentation of multiple organ/structure anatomies, and an accuracy study of 3D model generation. An added MRI validation, under a written protocol with pre-determined acceptance criteria and using multiple organ structures, radiologists, and view perspectives, demonstrated conservation of shape dimensions and volume versus a ground truth accepted standard. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Non-clinical performance data was included in the 510(k) submission to demonstrate that the Aibolit software has been validated for its intended use" … "Software verification and validation were performed, and documentation was included in this submission". Read from the exact FDA decision document on 2026-11-14.
No exact-submission and version-linked sensitivity endpoint is promoted; candidate or product-family values were not substituted.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No exact-submission and version-linked specificity endpoint is promoted; candidate or product-family values were not substituted.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
FDA submission-specific verification and validation evidence for K222458
DesignFDA 510(k) regulatory decision material and submission-specific verification or validation evidence for K222458; this is regulatory evidence, not an independent clinical effectiveness study.
PopulationThe labeled population, anatomy, images, and test materials described in the exact FDA decision material for K222458; a broader clinical population is not established here.
Scopeexact submission
Tested versionAIBOLIT 3D+ (K222458)
IndependenceSponsor or vendor study
K222458
The exact FDA material is submission-specific and should not be generalized to other versions, enabled options, sites, protocols, or clinical outcomes.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM or other medical-image data from the exact labeled modalities, scanners, and user workflow.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA indication establishes CT and MR image input and communication or media interchange; local DICOM, identity, export, display, and intraoperative integration require confirmation.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Aibolit 3D+ as a web-based stand-alone application that can be presented on a computer connected to the internet. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Aibolit 3D+ is a web-based stand-alone application that can be presented on a computer connected to the internet.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Images, measurements, segmentations, models, reports, or planning information for professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Aibolit 3D+ as a web-based stand-alone application that can be presented on a computer connected to the internet. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Aibolit 3D+ is a web-based stand-alone application that can be presented on a computer connected to the internet.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA indication establishes CT and MR image input and communication or media interchange; local DICOM, identity, export, display, and intraoperative integration require confirmation.
The exact FDA indication establishes CT and MR image input and communication or media interchange; local DICOM, identity, export, display, and intraoperative integration require confirmation.
exact submission · checked 2026-09-04
Validate the local workflow against the exact release and enabled options.
Current vendor material is product-family context for K222458 only; exact release, enabled options, deployment, security, interoperability, pricing, and local workflow require confirmation.
product family · checked 2026-09-04
Vendor material is not exact-release evidence unless that linkage is separately proven.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
31Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not applicable - checked 2026-09-04 - Not applicable
CMS coverage-index context was checked, but no product-specific coverage or reimbursement determination is inferred.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Public sources reviewed here do not establish the complete exact-release security posture, including identity, audit, encryption, retention, remote access, vulnerability management, backup, or incident response.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Beijing Infervision Healthcare Medical Technology Co., Ltd.
Authorized purpose: InferOperate Suite supports trained healthcare professionals in reading, interpreting, reporting, and treatment planning from medical images, with the submission's machine-learning functions applied to adult chest, abdomen, and pelvis CT.
Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Chest; abdomen; pelvis; and general patient anatomy represented in supported images
Authorized purpose: Clever One is dental imaging software for trained professionals to view and interpret DICOM images from CT, panoramic, cephalometric, intraoral, and other imaging equipment, with two-dimensional analysis and three-dimensional visualization tools.
Modality
Radiological images; modality varies or is not specified in FDA list
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.